Buscar
Mostrando ítems 1-10 de 17
In vitro inhibitory effect of maraviroc on the association of the simian immunodeficiency virus envelope glycoprotein with CCR5
(Springer, 2021-02)
Asian macaques infected with simian immunodeficiency viruses (SIVs) isolated from African non-human primates develop a disease similar to human AIDS. SIV enters its target cells by binding to CD4 and a coreceptor, typically ...
Seguridad hepática de maraviroc en pacientes coinfectados con VIH y hepatitis C y/o B
(Elsevier Doyma, 2017-12)
Cartas al Editor
Evaluation of Primary Resistance to HIV Entry Inhibitors Among Brazilian Patients Failing Reverse Transcriptase/Protease Inhibitors Treatment Reveal High Prevalence of Maraviroc Resistance-Related Mutations
(MARY ANN LIEBERT INC, 2010)
Entry inhibitor is a new class of drugs that target the viral envelope protein. This region is variable; hence resistance to these drugs may be present before treatment. The aim of this study was to analyze the frequency ...
Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 044-SDEPFYOTS-DETS-IETSI-2016. Eficacia y seguridad del uso de maraviroc para el tratamiento de VIH-1 con tropismo CCR5 positivo, en pacientes multidrogorresistentes en estadio sida
(Seguro Social de Salud (EsSalud), 2016-07)
En este documento se plasma la evaluación de la eficacia y seguridad del uso del producto farmacéutico maraviroc para el tratamiento de VIH-1 con tropismo CCR5 positivo, en pacientes multidrogorresistentes en estadio SIDA; ...
Use of third line antiretroviral therapy in Latin America
(Public Library of Science, 2014)
© PLOS ONE 2014. Background: Access to highly active antiretroviral therapy (HAART) is expanding in Latin America. Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination ...
Approach to establishing and evaluating clinical relevance of drugs interactions in HIV patients : 2009 updateAproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en pacientes infectados con virus de la inmunodeficiencia humana : actualización 2009
(Sociedad Española de Farmacia Hospitalaria (SEFH)ElsevierPromoción y Prevención FarmacéuticaMadrid, España, 2021)